Company Analysis Clinuvel Pharmaceuticals Limited
1. Summary
Advantages
- Price (6.92 $) is less than fair price (10.08 $)
- Current debt level 0.3807% is below 100% and has decreased over 5 years from 0.695%.
- The company's current efficiency (ROE=22.79%) is higher than the sector average (ROE=12.15%)
Disadvantages
- Dividends (0.3148%) are below the sector average (2.17%).
- The stock's return over the last year (-33.3%) is lower than the sector average (3.16%).
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Clinuvel Pharmaceuticals Limited | Healthcare | Index | |
|---|---|---|---|
| 7 days | -5.4% | -0.9% | 1.1% |
| 90 days | -5.3% | -2.8% | 9.1% |
| 1 year | -33.3% | 3.2% | 12.4% |
CLVLY vs Sector: Clinuvel Pharmaceuticals Limited has significantly underperformed the "Healthcare" sector by -36.46% over the past year.
CLVLY vs Market: Clinuvel Pharmaceuticals Limited has significantly underperformed the market by -45.65% over the past year.
Stable price: CLVLY is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: CLVLY with weekly volatility of -0.6404% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (6.92 $) is lower than the fair price (10.08 $).
Price significantly below the fair price: The current price (6.92 $) is 45.7% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (14.62) is lower than that of the sector as a whole (38.28).
P/E vs Market: The company's P/E (14.62) is lower than that of the market as a whole (59.99).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.57) is lower than that of the sector as a whole (3.52).
P/BV vs Market: The company's P/BV (2.57) is lower than that of the market as a whole (3.41).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (5.91) is higher than that of the sector as a whole (3.74).
P/S vs Market: The company's P/S indicator (5.91) is higher than that of the market as a whole (3.65).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (6.01) is lower than that of the sector as a whole (13.51).
EV/Ebitda vs Market: The company's EV/Ebitda (6.01) is lower than that of the market as a whole (40.09).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 22.94% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (22.94%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.61%).
5.4. ROE
ROE vs Sector: The company's ROE (22.79%) is higher than that of the sector as a whole (12.15%).
ROE vs Market: The company's ROE (22.79%) is lower than that of the market as a whole (41.13%).
5.5. ROA
ROA vs Sector: The company's ROA (19.75%) is higher than that of the sector as a whole (6.06%).
ROA vs Market: The company's ROA (19.75%) is lower than that of the market as a whole (29.31%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (19.97%) is higher than that of the sector as a whole (15.34%).
ROIC vs Market: The company's ROIC (19.97%) is higher than that of the market as a whole (11.01%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0.3148% is below the average for the sector '2.17%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0.3148% has been steadily paid over the past 7 years, DSI=1.
Weak dividend growth: The company's dividend yield 0.3148% has been growing weakly or stagnant over the past 5 years. Growth over only 3 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (4.63%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
